bioAffinity Technologies, Inc.
BIAFNASDAQHealthcare● Active
$1.60
$-0.13(-7.51%)
Market Cap$7255850
P/E Ratio—
52W High$13.8
52W Low$0.693
bioAffinity Technologies, Inc. (BIAF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BIAF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $6.16M | $9.36M | $2.53M | $0.00M | $0.00M |
| Cost of Revenue | $4.73M | $5.98M | $1.74M | $0.00M | $0.00M |
| Gross Profit | $1.43M | $3.38M | $0.79M | $0.00M | ($0.00M) |
| Gross Margin %(computed) | 23.21% | 36.09% | 31.26% | 90.28% | — |
| Operating Expenses | |||||
| R&D Expenses | $2.09M | $1.78M | $1.73M | $1.52M | $1.14M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.88M |
| Total Operating Expenses | $12.00M | $12.33M | $8.77M | $4.02M | $2.20M |
| Operating Income | ($10.57M) | ($8.95M) | ($7.97M) | ($4.01M) | ($2.21M) |
| Operating Margin %(computed) | -171.58% | -95.63% | -314.89% | — | — |
| Interest Income | $0.02M | $0.02M | $0.12M | $0.05M | $0.00M |
| Interest Expense | $0.04M | $0.09M | $0.04M | $2.53M | $1.00M |
| Income Before Tax | ($14.87M) | ($9.03M) | ($7.92M) | ($8.15M) | ($6.32M) |
| Income Tax Expense | $0.04M | $0.01M | $0.02M | $0.00M | $0.00M |
| Net Income | ($14.91M) | ($9.04M) | ($7.94M) | ($8.15M) | ($6.33M) |
| Net Margin %(computed) | -241.96% | -96.56% | -313.47% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-8.66 | $-22.50 | $-27.30 | $-54.30 | $-70.86 |
| Wtd Avg Shares | 1.72M | 0.40M | 0.29M | 0.15M | 0.09M |
| EBITDA | ($10.07M) | ($8.33M) | ($7.63M) | ($5.61M) | ($5.32M) |
| EBITDA Margin %(computed) | -163.38% | -88.98% | -301.30% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more bioAffinity Technologies, Inc. data
About bioAffinity Technologies, Inc. (BIAF) Income Statement
bioAffinity Technologies, Inc. (BIAF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BIAF reported revenue of $0.01B, gross profit of $0.00B (gross margin 23.21%), and net income of ($0.01B) — a net profit margin of -241.96%.
Frequently asked questions
BIAF · 4 questionsbioAffinity Technologies, Inc. (BIAF) reported revenue of $0.01B for 2025, down 34.2% year-over-year.
BIAF revenueBIAF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09